公开(公告)号：US20240400685A1

公开(公告)日：2024-12-05

申请号：US18664757

申请日：2024-05-15

Applicant: GENMAB A/S

Inventor： Richard G. HIBBERT ,  Bolette BJERREGAARD ,  Søren S. JENSEN ,  César Filipe OLIVEIRA DA COSTA ,  Rohan O'DONNELL

IPC: C07K16/28 ,  C07K1/18 ,  C07K1/34

Abstract: The present disclosure provides highly purified epcoritamab compositions, which comprise a bispecific antibody that binds CD3 and CD20. In the highly purified compositions, impurities, such as epcoritamab protein variants, process-related impurities and/or product-related impurities, have been minimized or removed. Methods of preparing the highly purified epcoritamab compositions are also provided.

公开(公告)号：US20220411505A1

公开(公告)日：2022-12-29

申请号：US17635258

申请日：2020-08-14

Applicant: GENMAB A/S

Inventor： Jesper VALBJOERN ,  Lene Schantz HARLOW ,  Jacob Dahlqvist CLAUSEN ,  Mette Hamborg JENSEN ,  Christian CIMANDER ,  Jesper PASS ,  Peter Juul MADSEN ,  Shan REN ,  Maria Anna Cecilia WAHLBOM ,  Bolette BJERREGAARD

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to improved pharmaceutical compositions and dosage unit forms of bispecific CD3×CD20 antibodies and to routes of administration.